Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Piyush Goyal Pushes Pharma Innovation as Industry Shrugs Off U.S. Tariff Concerns
The discussions took place against the backdrop of proposed U.S. tariffs that could impose a 100% duty on certain branded and patented drugs. The move, aimed at encouraging companies to shift production to the U.S., has sparked global debate — but Indian pharma leaders remain largely unshaken.
- By Newsdesk
- New Delhi
- Nov 25, 2025
Commerce and Industry Minister Piyush Goyal met top pharmaceutical industry leaders to accelerate India’s push toward innovation-driven growth, stronger regulatory frameworks, and expanded domestic manufacturing. The meeting focused on advancing research and development, boosting long-term investments, and strengthening India’s position as a global pharma hub.
Goyal emphasized the government’s commitment to creating an ecosystem that nurtures cutting-edge drug development while ensuring affordability and accessibility. He highlighted ongoing efforts to streamline regulatory processes, support high-value manufacturing, and draw global capital into India’s life sciences sector.
The discussions took place against the backdrop of proposed U.S. tariffs that could impose a 100% duty on certain branded and patented drugs. The move, aimed at encouraging companies to shift production to the U.S., has sparked global debate — but Indian pharma leaders remain largely unshaken.
According to industry representatives, India’s stronghold in generic medicines and APIs insulates it from the brunt of the proposed tariff regime, which primarily targets high-value patented drugs. Sector experts echoed this confidence, noting that generics form the bulk of India’s pharmaceutical exports to the U.S.
Trade data underscores the significance of the American market: around 31% of India’s total drug exports are shipped to the U.S., including nearly half of its generic drug shipments. In September 2025 alone, exports to the U.S. were valued at approximately USD 2.62 billion, reflecting the resilience of the sector even amid policy uncertainty.
As both industry and government align on a shared vision, India’s pharmaceutical sector appears poised not only to weather global trade disruptions but to advance further as an innovation-led global force.